Clinical trial
A Notch Signalling Pathway Inhibitor for Patients With Advanced Breast Cancer…
NCT00106145 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00106145 |
|---|---|
| Title | A Notch Signalling Pathway Inhibitor for Patients With Advanced Breast Cancer (0752-014) |
| Official title | A Phase I Study of MK0752, a Notch Inhibitor, in Patients With Metastatic or Locally Advanced Breast Cancer and Other Solid Tumors |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Advanced Breast Cancer, Other Solid Tumors |
| Intervention type | Drug |
| Interventions | Comparator: MK0752, Notch Inhibitor, Notch Inhibitor - 450 mg, Notch Inhibitor - 3 days on, 4 off, Notch Inhibitor - 1 day on, 6 off, 4 off 350 mg |
| Enrollment | 103 |
| Start date | Apr 1, 2005 |
| Primary completion | Aug 1, 2011 |
| Completion | Aug 1, 2011 |
| First posted | Mar 22, 2005 |
| Last update posted | Jan 30, 2015 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: